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Supplementary	  Table	  1.	  Mean	  absolute	  concentrations	  of	  lipoprotein,	  fatty	  acid	  and	  
metabolite	  measures	  in	  the	  study	  population,	  and	  absolute	  concentration	  changes	  
associated	  with	  starting	  statin	  therapy	  and	  rs12916	  in	  HMGCR.	  
Supplementary	  Table	  2.	  Clinical	  characteristics	  of	  the	  eight	  study	  populations	  used	  for	  the	  
genetic	  analyses	  stratified	  by	  rs12916	  genotype.	  
Supplementary	  Figure	  1.	  Representative	  NMR	  spectra	  before	  and	  after	  statin	  use.	  
Supplementary	  Figure	  2.	  Lipid	  and	  metabolite	  changes	  associated	  with	  starting	  statin	  
therapy	  relative	  to	  baseline	  concentrations.	  
Supplementary	  Figure	  3A-­‐F.	  Lipid	  and	  metabolite	  changes	  associated	  with	  starting	  statin	  
therapy	  and	  rs12196	  in	  HMGCR	  separately	  for	  the	  individual	  cohorts.	  
Supplementary	  Figure	  4.	  Lipid	  and	  metabolite	  changes	  associated	  with	  starting	  statin	  
therapy	  when	  adjusted	  for	  additional	  cardiovascular	  risk	  factors.	  
Supplementary	  Figure	  5.	  Comparison	  of	  lipid	  and	  metabolite	  associations	  for	  two	  common	  
genetic	  variants	  in	  the	  HMGCR	  gene.	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Supplementary	  Methods	  
Study	  populations	  
Longitudinal	  analyses:	  Lipid	  and	  metabolite	  associations	  with	  starting	  statin	  therapy	  
Southall	  and	  Brent	  Revisited	  (SABRE)	  	  
The	  SABRE	  study	  examined	  4,857	  individuals	  in	  a	  tri-­‐ethnic	  community-­‐based	  cohort	  from	  North	  and	  
West	  London,	  UK	  (www.sabrestudy.org).	  Details	  of	  the	  cohort	  have	  been	  published.1,2	  Briefly,	  
participants	  aged	  40	  to	  69	  at	  baseline	  (1988	  through	  1991)	  were	  selected	  randomly	  from	  5-­‐year	  age-­‐	  
and	  sex-­‐stratified	  primary	  care	  physician	  lists.	  Participants	  included	  Europeans	  (48%),	  Indian	  Asians	  
(47%)	  and	  a	  small	  fraction	  of	  African	  Caribbeans	  (5%).	  Participants	  attended	  a	  baseline	  clinic	  after	  an	  
overnight	  fast.	  Fasting	  blood	  samples	  were	  drawn	  for	  Southall	  participants	  and	  stored	  at	  −80°C	  for	  
biomarker	  measurements.	  Study	  participants	  were	  invited	  for	  a	  follow-­‐up	  visit	  during	  2008	  through	  
2011.	  NMR	  metabolomics	  was	  measured	  for	  3,298	  baseline	  serum	  samples	  with	  available	  stored	  
aliquots.3	  Among	  these,	  919	  attended	  the	  follow-­‐up	  survey	  in	  2008-­‐2011,	  and	  had	  the	  serum	  
metabolomic	  profiling	  done	  also	  at	  the	  follow-­‐up.4,5	  None	  of	  these	  study	  participants	  used	  lipid-­‐
lowering	  therapy	  at	  the	  1988-­‐1991	  baseline.	  Study	  questionnaires	  asked	  for	  the	  use	  of	  medication,	  
including	  the	  type	  of	  medication;	  98.3%	  out	  of	  the	  536	  individuals	  on	  lipid-­‐lowering	  medication	  at	  
follow-­‐up	  were	  using	  statins.	  The	  seven	  individuals	  on	  ezetimibe	  and	  four	  individuals	  on	  fibrate	  
mono-­‐therapy	  were	  omitted,	  leaving	  908	  individuals	  for	  the	  present	  analyses.	  Information	  on	  
HMGCR	  genotype	  was	  not	  available	  in	  this	  cohort.	  All	  participants	  gave	  written	  informed	  consent.	  
The	  study	  protocols	  were	  approved	  by	  the	  University	  College	  London	  and	  St.	  Mary’s	  Hospital	  
research	  ethics	  committees.	  
	  
The	  Pieksämäki	  cohort	  
The	  Pieksämäki	  cohort	  study	  consisted	  of	  individuals	  from	  the	  town	  of	  Pieksämäki,	  Eastern	  Finland,	  
born	  in	  1942,	  1947,	  1952,	  1957	  and	  1962.	  There	  were	  923	  participants	  in	  the	  initial	  examination	  in	  
1997,	  and	  690	  of	  these	  attended	  a	  follow-­‐up	  survey	  6.5-­‐years	  later	  (2003–2004).4,5	  In	  the	  present	  
study,	  668	  individuals	  with	  NMR-­‐based	  metabolomics	  measured	  from	  fasting	  serum	  samples	  at	  both	  
time-­‐points,	  and	  free	  of	  statin	  or	  other	  lipid-­‐lowering	  medication	  (n=16	  excluded)	  at	  baseline,	  were	  
analyzed.	  Among	  these,	  106	  had	  initiated	  statin	  therapy	  during	  follow-­‐up.	  No	  genotype	  information	  
was	  available	  in	  this	  cohort.	  Participants	  gave	  written	  informed	  consent	  and	  the	  study	  protocol	  was	  
approved	  by	  the	  Ethics	  Committee	  of	  Kuopio	  University	  Hospital,	  Finland.	  
	  
The	  Cardiovascular	  Risk	  in	  Young	  Finns	  Study	  (YFS)	  
The	  Cardiovascular	  Risk	  in	  Young	  Finns	  Study	  was	  initiated	  to	  study	  associations	  of	  childhood	  risk	  
factors	  to	  cardiovascular	  disease	  in	  adulthood	  (youngfinnsstudy.utu.fi).6	  The	  baseline	  study	  in	  1980	  
included	  3,596	  children	  and	  adolescents	  aged	  3–18.	  Metabolomics	  data	  in	  the	  longitudinal	  analyses	  
of	  the	  present	  study	  are	  based	  on	  the	  2007→2011	  surveys	  with	  2,160	  and	  2,040	  participants	  having	  
metabolomics	  measured	  from	  fasting	  serum	  samples	  collected	  in	  2007	  and	  2011,	  respectively.7,8	  
Among	  these,	  1,744	  participants	  had	  their	  metabolomic	  profile	  measured	  from	  both	  surveys.	  After	  
exclusion	  of	  individuals	  on	  lipid-­‐lowering	  medication	  at	  baseline	  (n=37)	  or	  missing	  treatment	  
information	  (n=105)	  and	  pregnant	  women	  (n=39),	  the	  present	  study	  comprised	  1,562	  individuals	  
with	  an	  NMR-­‐based	  metabolomics	  measured	  at	  both	  time-­‐points.	  These	  individuals	  were	  
representative	  of	  the	  original	  cohort.7	  Study	  questionnaires	  addressed	  the	  type	  of	  lipid-­‐lowering	  
medication.	  At	  4-­‐year	  follow-­‐up,	  43	  individuals	  had	  initiated	  statin	  therapy.	  A	  single	  individual	  
reporting	  to	  use	  only	  non-­‐statin	  lipid-­‐lowering	  treatment	  was	  excluded,	  whereas	  two	  individuals	  
reporting	  to	  initiate	  combination	  therapy	  were	  counted	  as	  statin	  starters.	  
In	  addition	  to	  longitudinal	  data,	  YFS	  also	  contributed	  to	  the	  Mendelian	  randomization	  
analyses	  of	  HMGCR.	  Genotype	  information	  on	  the	  two	  genetic	  variants	  (rs12196	  and	  rs17238484)	  in	  
HMGCR	  was	  available	  for	  n=1,905	  participants	  from	  the	  2007	  field	  study	  after	  exclusion	  of	  
	   3	  (24)	  
	   	  
individuals	  on	  lipid-­‐lowering	  medication	  and	  pregnant	  women	  at	  this	  timepoint.	  Genotype	  data	  was	  
based	  on	  670k	  Illumina	  HumanHap	  arrays.8	  Both	  common	  single	  nucleotide	  polymorphisms	  (SNPs)	  
were	  imputed	  based	  on	  the	  1000	  Genome	  reference	  panel.	  All	  participants	  gave	  written	  informed	  
consent.	  The	  study	  was	  approved	  by	  the	  ethics	  committees	  of	  each	  of	  the	  five	  participating	  medical	  
university	  study	  sites	  in	  Finland.	  
	  
The	  Avon	  Longitudinal	  Study	  of	  Parents	  and	  Children	  (ALSPAC)	  –	  Mothers	  Cohort	  
The	  Avon	  Longitudinal	  Study	  of	  Parents	  and	  Children	  was	  established	  to	  understand	  how	  genetic	  and	  
environmental	  characteristics	  influence	  health	  and	  development	  in	  parents	  and	  children	  
(bristol.ac.uk/alspac).9	  All	  pregnant	  women	  resident	  in	  a	  defined	  area	  in	  the	  South	  West	  of	  England,	  
with	  an	  expected	  date	  of	  delivery	  between	  1st	  April	  1991	  and	  31st	  December	  1992,	  were	  eligible	  and	  
13,761	  women	  were	  recruited.	  These	  mothers	  have	  been	  followed	  over	  more	  than	  two	  decades.9	  
NMR-­‐based	  metabolomics	  was	  measured	  from	  plasma	  samples	  collected	  during	  two	  follow-­‐up	  clinic	  
assessments;	  the	  first	  occurring	  between	  2009	  and	  2011	  (17-­‐19	  years	  after	  the	  index	  pregnancies)	  
and	  the	  second	  2011-­‐2012	  (19-­‐20	  years	  after	  the	  index	  pregnancies).	  For	  the	  first	  assessment,	  about	  
10,000	  women	  who	  remained	  engaged	  with	  the	  study	  were	  invited	  and	  50%	  attended.	  For	  the	  
second	  a	  3,000	  subsample	  of	  the	  first	  assessment	  who	  were	  anticipated	  to	  go	  through	  a	  menopausal	  
status	  transition	  were	  invited	  and	  over	  85%	  attended.	  At	  both	  assessments	  women	  attended	  after	  an	  
overnight	  fast	  for	  those	  attending	  in	  the	  morning	  or	  minimum	  6-­‐hours	  fast	  for	  those	  attending	  in	  the	  
afternoon.9	  	  
	   Metabolomics	  data	  were	  measured	  from	  stored	  EDTA	  plasma	  samples	  for	  4,524	  women	  in	  
the	  first	  assessment	  and	  2,749	  women	  in	  the	  second	  assessment.	  Altogether	  2,487	  women	  had	  their	  
metabolomic	  profile	  measured	  at	  both	  time-­‐points.	  Thirty-­‐five	  of	  these	  women	  were	  excluded	  
because	  they	  were	  using	  statins	  at	  the	  first	  (baseline)	  assessment,	  resulting	  in	  2,452	  women	  with	  
NMR-­‐based	  metabolomics	  measured	  at	  both	  time-­‐points	  included	  in	  the	  present	  analyses.	  	  
	   During	  the	  clinical	  assessments	  participants	  were	  asked	  to	  provide	  details	  of	  all	  medications	  
that	  they	  were	  using,	  including	  bringing	  medicine	  containers	  and	  prescriptions.	  All	  medications	  were	  
entered	  in	  a	  database	  with	  text	  names	  and	  information	  on	  dosage	  and	  frequency	  and	  the	  reason	  the	  
woman	  gave	  for	  taking	  the	  medication.	  The	  medication	  data	  was	  encoded	  to	  indicate	  which	  women	  
were	  taking	  statins	  at	  each	  time	  point.	  This	  was	  done	  by	  searching	  for	  all	  statin	  names	  that	  appeared	  
in	  the	  2014	  electronic	  version	  of	  the	  British	  National	  Formulary.	  This	  was	  supplemented	  by	  searching	  
for	  any	  reference	  to	  ‘cholesterol’,	  ‘blood	  fats’,	  ‘heart	  disease’,	  ‘heart	  attack’,	  ‘angina’	  and	  ‘heart’	  in	  
text	  entries	  to	  identify	  common	  misspellings	  of	  drug	  names,	  which	  were	  then	  used	  to	  undertake	  
additional	  searches.	  No	  other	  lipid	  lowering	  drugs	  were	  used	  in	  the	  cohort.	  	  
	   In	  addition	  to	  longitudinal	  data,	  ALSPAC	  mothers	  also	  contributed	  to	  the	  Mendelian	  
randomization	  analyses	  of	  HMGCR.	  Genotype	  information	  and	  population	  stratification	  was	  
obtained	  from	  Illumina	  Human660W-­‐Quad	  BeadChips	  run	  at	  Centre	  National	  de	  Génotypage,	  Evry,	  
France.	  Data	  on	  genotype	  and	  metabolomic	  profile	  from	  the	  first	  (2009-­‐2011)	  follow-­‐up	  assessment	  
were	  used	  in	  the	  Mendelian	  randomization	  analyses	  with	  these	  data	  available	  on	  3,137	  women	  after	  
exclusion	  of	  53	  on	  statin	  therapy.	  rs698912	  was	  used	  as	  proxy	  for	  the	  validation	  variant	  rs17238484,	  
linkage	  disequilibrium	  R2=1.	  The	  study	  was	  approved	  by	  the	  ALSPAC	  Law	  and	  Ethics	  Committee	  and	  
the	  UK	  National	  Health	  Service	  Research	  Ethics	  Committee	  and	  all	  participants	  provided	  written	  
informed	  consent.	  
	  
Genetic	  analyses:	  Lipid	  and	  metabolite	  associations	  with	  common	  variants	  in	  HMGCR	  
Northern	  Finland	  Birth	  Cohort	  of	  1986	  (NFBC	  1986)	  
The	  Northern	  Finland	  Birth	  Cohorts	  of	  1986	  and	  1966	  were	  initiated	  to	  study	  factors	  affecting	  
preterm	  birth	  and	  subsequent	  morbidity	  in	  the	  two	  northernmost	  provinces	  in	  Finland	  
(www.oulu.fi/nfbc).	  For	  NFBC	  1986,	  the	  number	  of	  deliveries	  in	  the	  birth	  cohort	  was	  9,362,	  which	  
was	  99%	  of	  all	  the	  deliveries	  taking	  place	  in	  the	  area	  during	  the	  target	  period	  (July	  1985-­‐June	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  (24)	  
	   	  
1986).10,11	  Data	  collection	  in	  2001–2002	  included	  clinical	  examination	  and	  serum	  sampling	  at	  age	  15–
16	  for	  6,621	  adolescents;	  attendees	  in	  the	  16-­‐year	  field	  study	  (71%)	  were	  representative	  of	  the	  
original	  cohort.12	  Metabolomics	  data	  from	  this	  timepoint	  were	  used	  for	  the	  genetic	  analyses	  in	  the	  
present	  study.	  NMR	  metabolomics	  was	  measured	  for	  5,602	  serum	  samples,	  of	  which	  95%	  were	  
drawn	  after	  overnight	  fasting.8	  Among	  these,	  4,145	  individuals	  had	  information	  available	  on	  the	  
rs12196	  variant	  in	  HMGCR	  from	  the	  CardioMetabochip	  and	  genomic	  information	  on	  population	  
stratification.	  The	  SNP	  rs3761742	  was	  used	  as	  proxy	  for	  the	  validation	  variant	  rs17238484	  (linkage	  
disequilibrium	  R2=1).	  Informed	  written	  consent	  was	  obtained	  from	  all	  participants.	  The	  research	  
protocols	  were	  approved	  by	  the	  Ethics	  Committee	  of	  Northern	  Ostrobotnia	  Hospital	  District,	  Finland.	  
	  
Northern	  Finland	  Birth	  Cohort	  of	  1966	  (NFBC	  1966)	  
The	  NFBC	  1966	  included	  12,058	  children	  born	  into	  the	  cohort,	  comprising	  96%	  of	  all	  births	  during	  
1966	  in	  the	  region	  (www.oulu.fi/nfbc).13,14	  Data	  collection	  in	  1997	  included	  clinical	  examination	  and	  
serum	  sampling	  at	  age	  31	  for	  6,007	  individuals.	  Metabolomics	  data	  from	  this	  time	  point	  were	  used	  
for	  the	  genetic	  analyses	  in	  the	  present	  study.	  Attendees	  in	  the	  31-­‐year	  field	  study	  (52%)	  were	  
representative	  of	  the	  original	  cohort.14	  NMR-­‐based	  metabolomics	  was	  measured	  from	  5,709	  
individuals	  with	  serum	  sample	  available,	  of	  which	  96%	  were	  fasting	  samples.	  Among	  these,	  4,920	  
individuals	  had	  genotype	  information	  on	  rs12196	  and	  rs17238484	  variants	  in	  the	  HMGCR	  gene	  
based	  on	  370k	  Illumina	  HumanHap	  arrays.13	  Both	  common	  SNPs	  were	  imputed	  based	  on	  the	  1000	  
Genome	  reference	  panel.	  Pregnant	  women	  were	  omitted	  from	  the	  genetic	  analyses.	  Informed	  
written	  consent	  was	  obtained	  from	  all	  participants.	  The	  research	  protocols	  were	  approved	  by	  the	  
Ethics	  Committee	  of	  Northern	  Ostrobotnia	  Hospital	  District,	  Finland.	  	  
	  
FINRISK	  1997	  
The	  FINRISK	  1997	  study	  was	  conducted	  to	  monitor	  the	  health	  of	  the	  Finnish	  population	  among	  
persons	  aged	  25–74	  at	  recruitment	  (thl.fi/finriski).3	  In	  total,	  8,444	  individuals	  were	  recruited	  to	  
represent	  the	  middle-­‐aged	  population	  of	  five	  study	  locations	  across	  Finland.	  Participants	  completed	  
questionnaires	  on	  use	  of	  lipid-­‐lowering	  medication.	  Information	  on	  medication	  was	  complemented	  
by	  national	  reimbursement	  records.	  Serum	  samples	  were	  stored	  at	  –70°C	  for	  later	  biomarker	  
analyses.	  Samples	  were	  semi-­‐fasting:	  participants	  were	  asked	  not	  to	  eat	  4	  hours	  prior	  to	  giving	  
blood.	  The	  median	  fasting	  time	  was	  5	  h	  (interquartile	  range	  4–6	  h).	  NMR	  metabolomics	  was	  
measured	  during	  2012	  for	  7,610	  participants	  with	  serum	  samples	  available.	  Among	  these,	  4,599	  
individuals	  had	  information	  on	  rs12196	  and	  rs17238484	  variants	  in	  the	  HMGCR	  gene	  based	  on	  670k	  
Illumina	  HumanHap	  arrays	  after	  exclusion	  of	  pregnant	  women	  (n=48)	  and	  individuals	  on	  lipid-­‐
lowering	  medication	  (n=148).	  Both	  common	  SNPs	  were	  imputed	  based	  on	  the	  1000	  Genome	  
reference	  panel.	  The	  study	  was	  approved	  by	  the	  Coordinating	  Ethical	  Committee	  of	  the	  Helsinki	  and	  
Uusimaa	  Hospital	  District,	  Finland.	  
	  
The	  Avon	  Longitudinal	  Study	  of	  Parents	  and	  Children	  (ALSPAC)	  –	  Children	  Cohort	  
The	  Avon	  Longitudinal	  Study	  of	  Parents	  and	  Children	  was	  established	  to	  understand	  how	  genetic	  and	  
environmental	  characteristics	  influence	  health	  and	  development	  in	  parents	  and	  children	  
(bristol.ac.uk/alspac).9	  Recruitment	  sought	  to	  enroll	  pregnant	  women	  in	  the	  Bristol	  area	  of	  the	  UK	  
during	  1990–92.	  Of	  the	  14,541	  pregnancies	  originally	  enrolled	  there	  were	  14,062	  live	  births	  of	  whom	  
13,988	  were	  still	  alive	  at	  12	  months.16	  Additional	  recruitment	  of	  children	  who	  were	  potentially	  in	  the	  
birth	  cohort	  has	  occurred	  since	  the	  children	  were	  aged	  7	  and	  this	  has	  resulted	  in	  a	  further	  706	  
participants.	  All	  eligible	  participants	  have	  been	  invited	  to	  follow-­‐up	  clinics	  since	  age	  7	  with	  
recruitment	  rates	  between	  45-­‐70%.	  NMR-­‐based	  metabolomics	  was	  measured	  from	  EDTA	  plasma	  
samples	  collected	  during	  follow-­‐up	  at	  age	  7,	  15,	  and	  17.	  Genotype	  information	  on	  HMGCR	  variants	  
were	  obtained	  from	  610k	  Illumina	  HumanHap	  arrays	  generated	  by	  Sample	  Logistics	  and	  Genotyping	  
Facilities	  at	  the	  Wellcome	  Trust	  Sanger	  Institute,	  UK,	  and	  LabCorp,	  USA.	  Genotype	  data	  were	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available	  for	  n=2,456	  adolescents	  with	  metabolomics	  data	  from	  the	  17-­‐year	  field	  survey	  (2009–
2010).	  rs698912	  was	  used	  as	  proxy	  for	  the	  validation	  variant	  rs17238484,	  linkage	  disequilibrium	  
R2=1.	  The	  study	  was	  approved	  by	  the	  ALSPAC	  Law	  and	  Ethics	  Committee	  and	  the	  UK	  National	  Health	  
Service	  Research	  Ethics	  Committee.	  The	  main	  caregiver	  initially	  provided	  consent	  for	  child	  
participation	  and	  from	  age	  16-­‐years	  the	  participants	  themselves	  have	  provided	  informed	  written	  
consent.	  	  
	  
British	  Women’s	  Heart	  and	  Health	  Study	  (BWHHS)	  
The	  British	  Women’s	  Heart	  and	  Health	  Study	  recruited	  4,286	  females	  between	  1999	  and	  2001,	  who	  
were	  randomly	  selected	  from	  23	  British	  towns	  and	  were	  aged	  between	  60	  and	  79	  years	  at	  
assessment	  (lshtm.ac.uk/eph/ncde/research/bwhhs).	  Data	  collection	  including	  blood	  sampling	  took	  
place	  between	  April	  1999	  and	  March	  2001.	  Methods	  used	  have	  been	  described	  in	  detail	  previously.17	  
Blood	  was	  drawn	  after	  a	  minimum	  of	  8-­‐hour	  fast	  and	  serum	  samples	  stored	  at	  −80°C.	  NMR	  
metabolomics	  was	  measured	  for	  3,777	  serum	  samples	  available	  during	  2012.3	  Among	  these,	  3,030	  
study	  participants	  had	  information	  available	  on	  rs12196	  variant	  in	  HMGCR	  and	  genomic	  population	  
stratification	  based	  on	  the	  Illumina	  CardioMetabochip	  and	  were	  free	  of	  lipid-­‐lowering	  medication	  at	  
baseline	  (n=233	  excluded).	  The	  SNP	  rs3761742	  was	  used	  as	  proxy	  for	  the	  validation	  variant	  
rs17238484	  (linkage	  disequilibrium	  R2=1).	  Local	  ethics	  committee	  approvals	  were	  obtained	  for	  the	  
BWHHS	  and	  all	  women	  provided	  informed	  written	  consent.	  
	  
Whitehall	  II	  Study	  (WHII)	  
The	  Whitehall	  II	  study	  was	  established	  in	  1985	  to	  investigate	  the	  importance	  of	  social	  class	  for	  health	  
by	  following	  a	  cohort	  of	  10,308	  civil	  servants	  (men	  and	  women)	  initially	  aged	  35–55	  years	  working	  in	  
the	  London	  offices	  of	  20	  Whitehall	  departments	  (ucl.ac.uk/whitehallII).	  Details	  of	  the	  study	  and	  
methods	  used	  have	  been	  described	  previously.18	  NMR-­‐based	  metabolomics	  was	  measured	  from	  
6,204	  fasting	  serum	  samples	  collected	  during	  the	  phase-­‐5	  clinical	  examination	  in	  1997–1999.	  Among	  
these,	  3,918	  study	  participants	  had	  information	  available	  on	  rs12196	  variant	  in	  HMGCR	  and	  genomic	  
population	  stratification	  based	  on	  the	  Illumina	  IBC	  HumanCVD	  BeadChip	  and	  were	  free	  of	  lipid-­‐
lowering	  medication.	  Local	  ethics	  committee	  approvals	  were	  obtained	  for	  the	  Whitehall	  II	  Study	  and	  
all	  participants	  provided	  informed	  written	  consent.	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Supplementary	  Table	  1.	  Mean	  absolute	  concentrations	  of	  lipoprotein,	  fatty	  acid	  and	  
metabolite	  measures	  in	  the	  study	  population	  and	  absolute	  concentration	  changes	  
associated	  with	  starting	  statin	  therapy	  and	  rs12916	  in	  HMGCR.	  
Metabolic	  measure	   Mean	  (SD)	   Absolute	  concentration	  




(meta-­‐analysis	  of	  716	  statin	  
starters	  and	  4,874	  non-­‐users)	  
Absolute	  difference	  per	  
T-­‐allele	  of	  rs12196	  in	  HMGCR	  
	  
Beta	  [95%CI]	  
(meta-­‐analysis	  of	  n=27,914)	  
Lipoprotein	  subclass	  particle	  concentrations	  

























Very	  small	  VLDL	  (µmol/L)	   0.039	  (0.010)	   -­‐0.012	  [-­‐0.013,	  -­‐0.011]	   -­‐0.0006	  [-­‐0.0008,	  -­‐0.0004]	  
IDL	  (µmol/L)	   0.099	  (0.023)	   -­‐0.038	  [-­‐0.040,	  -­‐0.035]	   -­‐0.0019	  [-­‐0.0023,	  -­‐0.0015]	  
Large	  LDL	  (µmol/L)	   0.16	  (0.04)	   -­‐0.065	  [-­‐0.068,	  -­‐0.061]	   -­‐0.0034	  [-­‐0.0040,	  -­‐0.0027]	  
Medium	  LDL	  (µmol/L)	   0.13	  (0.03)	   -­‐0.053	  [-­‐0.057,	  -­‐0.050]	   -­‐0.0028	  [-­‐0.0033,	  -­‐0.0022]	  
Small	  LDL	  (µmol/L)	   0.15	  (0.04)	   -­‐0.058	  [-­‐0.062,	  -­‐0.054]	   -­‐0.003	  [-­‐0.004,	  -­‐0.002]	  
Very	  large	  HDL	  (µmol/L)	   0.39	  (0.18)	   -­‐0.063	  [-­‐0.079,	  -­‐0.048]	   -­‐0.0014	  [-­‐0.0042,	  0.0014]	  
Large	  HDL	  (µmol/L)	   1.0	  (0.4)	   0.043	  [0.007,	  0.080]	   0.005	  [-­‐0.001,	  0.011]	  
Medium	  HDL	  (µmol/L)	   1.8	  (0.3)	   0.036	  [-­‐0.004,	  0.075]	   0.000031	  [-­‐0.0058,	  0.0059]	  
Small	  HDL	  (µmol/L)	   4.3	  (0.5)	   0.099	  [0.044,	  0.153]	   0.00085	  [-­‐0.0071,	  0.0088]	  
Cholesterol	  (C)	  
Total	  C	  (mmol/L)	   4.7	  (0.9)	   -­‐1.4	  [-­‐1.4,	  -­‐1.3]	   -­‐0.077	  [-­‐0.092,	  -­‐0.061]	  
Non-­‐HDL	  C	  (mmol/L)	   3.2	  (0.9)	   -­‐1.3	  [-­‐1.4,	  -­‐1.2]	   -­‐0.076	  [-­‐0.090,	  -­‐0.061]	  
Remnant	  C	  (mmol/L)	   1.5	  (0.4)	   -­‐0.51	  [-­‐0.54,	  -­‐0.47]	   -­‐0.03	  [-­‐0.04,	  -­‐0.02]	  
VLDL	  C	  (mmol/L)	   0.73	  (0.24)	   -­‐0.22	  [-­‐0.24,	  -­‐0.19]	   -­‐0.014	  [-­‐0.018,	  -­‐0.010]	  
IDL	  C	  (mmol/L)	   0.74	  (0.18)	   -­‐0.29	  [-­‐0.31,	  -­‐0.28]	   -­‐0.016	  [-­‐0.019,	  -­‐0.013]	  
LDL	  C	  (mmol/L)	   1.7	  (0.5)	   -­‐0.81	  [-­‐0.86,	  -­‐0.77]	   -­‐0.046	  [-­‐0.054,	  -­‐0.037]	  
HDL	  C	  (mmol/L)	   1.5	  (0.3)	   -­‐0.02	  [-­‐0.05,	  0.01]	   0.00036	  [-­‐0.00502,	  0.00575]	  
HDL2	  C	  (mmol/L)	   0.95	  (0.31)	   0.0017	  [-­‐0.025,	  0.028]	   0.00096	  [-­‐0.0037,	  0.0056]	  
HDL3	  C	  (mmol/L)	   0.52	  (0.04)	   -­‐0.022	  [-­‐0.027,	  -­‐0.018]	   -­‐0.0014	  [-­‐0.0023,	  -­‐0.0006]	  
Esterified	  C	  (mmol/L)	   3.4	  (0.7)	   -­‐0.97	  [-­‐1.03,	  -­‐0.90]	   -­‐0.053	  [-­‐0.064,	  -­‐0.041]	  
Free	  C	  (mmol/L)	   1.3	  (0.3)	   -­‐0.39	  [-­‐0.42,	  -­‐0.37]	   -­‐0.021	  [-­‐0.026,	  -­‐0.017]	  
Esterified	  C	  (%)	   72	  (	  2)	   0.081	  [-­‐0.138,	  0.299]	   0.00016	  [-­‐0.00049,	  0.00082]	  
Triglycerides	  (TG)	  
Total	  TG	  (mmol/L)	   1.2	  (0.5)	   -­‐0.20	  [-­‐0.26,	  -­‐0.15]	   -­‐0.017	  [-­‐0.025,	  -­‐0.008]	  
VLDL	  TG	  (mmol/L)	   0.72	  (0.43)	   -­‐0.095	  [-­‐0.143,	  -­‐0.047]	   -­‐0.011	  [-­‐0.017,	  -­‐0.004]	  
IDL	  TG	  (mmol/L)	   0.12	  (0.03)	   -­‐0.031	  [-­‐0.034,	  -­‐0.027]	   -­‐0.0016	  [-­‐0.0021,	  -­‐0.0010]	  
LDL	  TG	  (mmol/L)	   0.21	  (0.07)	   -­‐0.054	  [-­‐0.061,	  -­‐0.048]	   -­‐0.0033	  [-­‐0.0044,	  -­‐0.0021]	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HDL	  TG	  (mmol/L)	   0.12	  (0.04)	   -­‐0.017	  [-­‐0.021,	  -­‐0.013]	   -­‐0.00067	  [-­‐0.0013,	  -­‐0.00002]	  
Phospholipids	  (PL)	  
Total	  PL	  (mmol/L)	   3.0	  (0.4)	   -­‐0.41	  [-­‐0.46,	  -­‐0.37]	   -­‐0.024	  [-­‐0.032,	  -­‐0.017]	  
VLDL	  PL	  (mmol/L)	   0.45	  (0.17)	   -­‐0.12	  [-­‐0.14,	  -­‐0.10]	   -­‐0.0082	  [-­‐0.011,	  -­‐0.0054]	  
IDL	  PL	  (mmol/L)	   0.31	  (0.07)	   -­‐0.12	  [-­‐0.12,	  -­‐0.11]	   -­‐0.0064	  [-­‐0.0076,	  -­‐0.0052]	  
LDL	  PL	  (mmol/L)	   0.67	  (0.14)	   -­‐0.22	  [-­‐0.23,	  -­‐0.20]	   -­‐0.012	  [-­‐0.014,	  -­‐0.009]	  
HDL	  PL	  (mmol/L)	   1.6	  (0.3)	   0.039	  [0.010,	  0.068]	   0.0021	  [-­‐0.0032,	  0.0074]	  
Cholines	  (mmol/L)	   2.0	  (0.4)	   -­‐0.30	  [-­‐0.33,	  -­‐0.26]	   -­‐0.015	  [-­‐0.021,	  -­‐0.008]	  
Sphingomyelin	  (mmol/L)	   0.38	  (0.06)	   -­‐0.052	  [-­‐0.059,	  -­‐0.045]	   -­‐0.0038	  [-­‐0.0052,	  -­‐0.0023]	  
Phosphoglycerides	  (mmol/L)	   1.3	  (0.3)	   -­‐0.18	  [-­‐0.21,	  -­‐0.15]	   -­‐0.011	  [-­‐0.016,	  -­‐0.006]	  
Lipoprotein	  particle	  size	  
VLDL	  particle	  size	  (nm)	   36	  (	  1)	   0.26	  [0.13,	  0.38]	   -­‐0.0063	  [-­‐0.026,	  0.014]	  
LDL	  particle	  size	  (nm)	   24	  (	  0)	   0.0054	  [-­‐0.013,	  0.024]	   0.001	  [-­‐0.001,	  0.003]	  
HDL	  particle	  size	  (nm)	   10	  (	  0)	   -­‐0.029	  [-­‐0.048,	  -­‐0.009]	   -­‐0.000063	  [-­‐0.0037,	  0.0036]	  
Apolipoproteins	  
Apolipoprotein	  B	  (g/L)	   0.91	  (0.21)	   -­‐0.27	  [-­‐0.29,	  -­‐0.25]	   -­‐0.015	  [-­‐0.019,	  -­‐0.012]	  
Apolipoprotein	  A-­‐I	  (g/L)	   1.6	  (0.2)	   -­‐0.08	  [-­‐0.10,	  -­‐0.06]	   -­‐0.005	  [-­‐0.008,	  -­‐0.002]	  
Fatty	  acids	  
Total	  fatty	  acids	  (mmol/L)	   11	  (	  2)	   -­‐2.0	  [-­‐2.2,	  -­‐1.7]	   -­‐0.11	  [-­‐0.16,	  -­‐0.07]	  
Saturated	  fatty	  acids	  (mmol/L)	   3.8	  (1.0)	   -­‐0.69	  [-­‐0.79,	  -­‐0.59]	   -­‐0.038	  [-­‐0.055,	  -­‐0.021]	  
MUFA	  (mmol/L)	   3.0	  (0.9)	   -­‐0.41	  [-­‐0.49,	  -­‐0.32]	   -­‐0.026	  [-­‐0.041,	  -­‐0.010]	  
PUFA	  (mmol/L)	   4.0	  (0.8)	   -­‐0.81	  [-­‐0.89,	  -­‐0.73]	   -­‐0.049	  [-­‐0.062,	  -­‐0.035]	  
Omega-­‐6	  fatty	  acids	  (mmol/L)	   3.6	  (0.7)	   -­‐0.74	  [-­‐0.81,	  -­‐0.67]	   -­‐0.044	  [-­‐0.056,	  -­‐0.032]	  
Linoleic	  acid	  (mmol/L)	   3.0	  (0.6)	   -­‐0.74	  [-­‐0.81,	  -­‐0.68]	   -­‐0.043	  [-­‐0.053,	  -­‐0.033]	  
Omega-­‐3	  fatty	  acids	  (mmol/L)	   0.43	  (0.14)	   -­‐0.056	  [-­‐0.072,	  -­‐0.041]	   -­‐0.0045	  [-­‐0.0067,	  -­‐0.0023]	  
Docosahexaenoic	  acid	  
(mmol/L)	   0.17	  (0.06)	   -­‐0.015	  [-­‐0.020,	  -­‐0.009]	   -­‐0.0012	  [-­‐0.0022,	  -­‐0.0003]	  
Fatty	  acid	  ratios	  
Saturated	  fatty	  acids	  (%)	   35	  (	  2)	   0.083	  [-­‐0.230,	  0.40]	   0.042	  [0.008,	  0.075]	  
MUFA	  (%)	   27	  (	  3)	   0.77	  [0.42,	  1.12]	   0.0082	  [-­‐0.044,	  0.061]	  
PUFA	  (%)	   38	  (	  4)	   -­‐0.80	  [-­‐1.24,	  -­‐0.36]	   -­‐0.05	  [-­‐0.11,	  0.01]	  
Omega-­‐6	  fatty	  acids	  (%)	   34	  (	  4)	   -­‐0.89	  [-­‐1.31,	  -­‐0.46]	   -­‐0.049	  [-­‐0.101,	  0.004]	  
Linoleic	  acid	  (%)	   28	  (	  4)	   -­‐1.8	  [-­‐2.2,	  -­‐1.4]	   -­‐0.10	  [-­‐0.16,	  -­‐0.05]	  
Omega-­‐3	  fatty	  acids	  (%)	   4.0	  (1.0)	   0.26	  [0.14,	  0.39]	   -­‐0.0012	  [-­‐0.016,	  0.014]	  
Docosahexaenoic	  acid	  (%)	   1.6	  (0.5)	   0.15	  [0.10,	  0.20]	   0.0041	  [-­‐0.0029,	  0.011]	  
Degree	  of	  unsaturation	   1.2	  (0.1)	   0.0076	  [-­‐0.0018,	  0.017]	   0.00056	  [-­‐0.00065,	  0.0018]	  
Amino	  acids	  
Alanine	  (µmol/L)	   358	  (	  64)	   6.3	  [-­‐0.5,	  13.2]	   0.043	  [-­‐1.028,	  1.113]	  
Glutamine	  (µmol/L)	   516	  (	  84)	   4.9	  [-­‐3.5,	  13.4]	   0.62	  [-­‐0.57,	  1.81]	  
Glycine	  (µmol/L)	   308	  (	  62)	   -­‐2.4	  [-­‐8.1,	  3.3]	   0.10	  [-­‐0.96,	  1.16]	  
Branched-­‐chain	  amino	  acids	  
Isoleucine	  (µmol/L)	   52	  (15)	   -­‐2.2	  [-­‐3.5,	  -­‐0.8]	   -­‐0.16	  [-­‐0.40,	  0.08]	  
Leucine	  (µmol/L)	   81	  (19)	   -­‐1.1	  [-­‐2.8,	  0.7]	   -­‐0.042	  [-­‐0.281,	  0.197]	  
Valine	  (µmol/L)	   187	  (	  37)	   -­‐2.6	  [-­‐6.3,	  1.0]	   0.15	  [-­‐0.45,	  0.75]	  
Aromatic	  amino	  acids	  
	   9	  (24)	  
	   	  
Phenylalanine	  (µmol/L)	   75	  (12)	   -­‐2.4	  [-­‐3.7,	  -­‐1.1]	   -­‐0.022	  [-­‐0.188,	  0.145]	  
Tyrosine	  (µmol/L)	   56	  (12)	   -­‐1.1	  [-­‐2.3,	  0.0]	   0.042	  [-­‐0.154,	  0.237]	  
Histidine	  (µmol/L)	   69	  (13)	   -­‐1.8	  [-­‐3.2,	  -­‐0.4]	   0.023	  [-­‐0.161,	  0.207]	  
Glycolysis	  metabolites	  
Glucose	  (mmol/L)	   4.6	  (0.9)	   0.065	  [-­‐0.024,	  0.154]	   0.01	  [0.00,	  0.02]	  
Lactate	  (mmol/L)	   1.4	  (0.4)	   0.034	  [-­‐0.022,	  0.090]	   -­‐0.0048	  [-­‐0.012,	  0.0018]	  
Pyruvate	  (µmol/L)	   79	  (26)	   5.5	  [2.3,	  8.8]	   0.076	  [-­‐0.36,	  0.51]	  
Citrate	  (µmol/L)	   102	  (	  20)	   -­‐0.074	  [-­‐2.45,	  2.30]	   0.052	  [-­‐0.33,	  0.43]	  
Glycerol	  (µmol/L)	   94	  (33)	   1.5	  [-­‐2.9,	  5.9]	   -­‐0.64	  [-­‐1.32,	  0.05]	  
Ketone	  bodies	  
Acetoacetate	  (µmol/L)	   41	  (31)	   0.20	  [-­‐4.87,	  5.27]	   0.10	  [-­‐0.55,	  0.75]	  
Beta-­‐hydroxybutyrate	  
(µmol/L)	   105	  (	  73)	   -­‐9.5	  [-­‐20.1,	  1.2]	   -­‐0.39	  [-­‐2.21,	  1.42]	  
Miscellaneous	  
Creatinine	  (µmol/L)	   62	  (11)	   -­‐0.54	  [-­‐1.68,	  0.61]	   0.25	  [0.07,0.42]	  
Albumin	  (cu)	   0.094	  (0.007)	   -­‐0.00059	  [-­‐0.0013,	  0.00016]	   -­‐0.00014	  [-­‐0.00025,	  -­‐0.00002]	  
Acetate	  (µmol/L)	   57	  (21)	   -­‐3.4	  [-­‐5.4,	  -­‐1.3]	   -­‐0.13	  [-­‐0.35,	  0.10]	  
Inflammation	  
Glycoprotein	  acetyls	  (mmol/L)	   1.4	  (0.2)	   -­‐0.037	  [-­‐0.057,	  -­‐0.017]	   -­‐0.0032	  [-­‐0.0067,	  0.0004]	  
Mean	  concentrations	  of	  the	  metabolic	  measures	  and	  standard	  deviations	  (SD)	  were	  averaged	  across	  
the	  four	  longitudinal	  cohorts.	  Absolute	  concentration	  changes	  associated	  with	  starting	  statin	  therapy	  
are	  indicated,	  corresponding	  to	  the	  SD-­‐scaled	  values	  shown	  in	  the	  left	  columns	  of	  Figures	  1–3.	  The	  
associations	  of	  rs12916-­‐T	  allele	  with	  the	  metabolic	  measures	  in	  absolute	  concentration	  units	  are	  also	  
indicated,	  corresponding	  to	  the	  SD-­‐scaled	  values	  in	  the	  right	  columns	  of	  Figures	  1–3.	  
cu:	  standardized	  concentration	  units.	  
All	  the	  80	  lipoprotein,	  lipid	  and	  metabolite	  measures	  were	  quantified	  using	  the	  same	  
high-­‐throughput	  serum	  NMR	  metabolomics	  platform.19	  The	  14	  lipoprotein	  subclass	  sizes	  were	  
defined	  as	  follows:	  extremely	  large	  VLDL	  with	  particle	  diameters	  from	  75	  nm	  upwards	  and	  a	  possible	  
contribution	  of	  chylomicrons,	  five	  VLDL	  subclasses	  (average	  particle	  diameters	  of	  64.0	  nm,	  53.6	  nm,	  
44.5	  nm,	  36.8	  nm,	  and	  31.3	  nm),	  IDL	  (28.6	  nm),	  three	  LDL	  subclasses	  (25.5	  nm,	  23.0	  nm,	  and	  18.7	  
nm),	  and	  four	  HDL	  subclasses	  (14.3	  nm,	  12.1	  nm,	  10.9	  nm,	  and	  8.7	  nm).	  The	  mean	  size	  for	  VLDL,	  LDL	  
and	  HDL	  particles	  was	  calculated	  by	  weighting	  the	  corresponding	  subclass	  diameters	  with	  their	  
particle	  concentrations.	  
Remnant	  cholesterol	  was	  defined	  as	  VLDL-­‐cholesterol	  +	  IDL-­‐cholesterol,	  which	  is	  equivalent	  to	  
total-­‐cholesterol	  -­‐	  HDL-­‐cholesterol	  -­‐	  LDL-­‐cholesterol.20	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Supplementary	  Table	  2.	  Clinical	  characteristics	  of	  the	  eight	  study	  populations	  used	  for	  the	  genetic	  analyses	  stratified	  by	  rs12916	  genotype.	  
Values	  are	  mean	  (SD)	  and	  median	  [interquartile	  range]	  for	  normally	  distributed	  and	  skewed	  variables,	  respectively.	  P-­‐value	  of	  Hardy-­‐Weinberg	  equilibrium	  for	  
rs12196	  in	  HMGCR	  was	  P>0.01	  in	  all	  cohorts.	  
Characteristics	  
Avon	  Longitudinal	  Study	  of	  Parents	  and	  
Children:	  ALSPAC	  children	  
n=2,456	  
Avon	  Longitudinal	  Study	  of	  Parents	  and	  
Children:	  ALSPAC	  mothers	  
n=3,137	  
British	  Women’s	  Heart	  and	  Health	  Study	  
(BWHHS)	  
n=3,030	  
Genotype	   C/C	   C/T	   T/T	   C/C	   C/T	   T/T	   C/C	   C/T	   T/T	  
Number	  of	  individuals	   338	   1192	   926	   456	   1481	   1200	   483	   1459	   1088	  
Male	  [%]	   55	   50	   52	   0	   0	   0	   0	   0	   0	  
Age	  [year]	   17.8	  (0.4)	   17.8	  (0.4)	   17.8	  (0.4)	   47.9	  (4.2)	   47.8	  (4.3)	   48.0	  (4.3)	   68.3	  (5.4)	   69.0	  (5.5)	   68.8	  (5.7)	  
BMI	  [kg/m2]	   22.6	  (3.6)	   22.6	  (3.9)	   22.8	  (3.9)	   26.4	  (4.8)	   26.4	  (5.0)	   26.4	  (5.1)	   27.3	  (5.1)	   27.3	  (4.8)	   27.8	  (5.1)	  
Systolic	  blood	  pressure	  [mmHg]	   114	  (10)	   115	  (10)	   115	  (10)	   118	  (12)	   118	  (12)	   118	  (12)	   145	  (24)	   148	  (25)	   147	  (25)	  
Plasma	  glucose	  [mmol/L]	   5.0	  [4.7,5.3]	   5.0	  [4.8,5.2]	   5.0	  [4.8,5.3]	   5.2	  [4.9,5.5]	   5.1	  [4.9,5.4]	   5.2	  [4.9,5.4]	   5.8	  [5.4,6.1]	   5.7	  [5.4,6.1]	   5.7	  [5.4,6.1]	  
Triglycerides	  [mmol/L]	   0.8	  [0.6,1.0]	   0.8	  [0.6,1.0]	   0.8	  [0.6,1.0]	   0.9	  [0.7,1.2]	   0.9	  [0.7,1.2]	   0.9	  [0.7,1.1]	   1.5	  [1.2,2.2]	   1.6	  [1.2,2.2]	   1.6	  [1.2,2.3]	  
Total	  cholesterol	  [mmol/L]	   3.9	  (0.7)	   3.8	  (0.7)	   3.7	  (0.7)	   5.0	  (0.9)	   5.0	  (0.8)	   4.9	  (0.9)	   6.8	  (1.2)	   6.7	  (1.2)	   6.6	  (1.1)	  
HDL	  cholesterol	  [mmol/L]	   1.3	  (0.3)	   1.3	  (0.3)	   1.3	  (0.3)	   1.5	  (0.4)	   1.5	  (0.4)	   1.5	  (0.4)	   1.7	  (0.5)	   1.7	  (0.5)	   1.7	  (0.4)	  
Friedewald	  LDL	  cholesterol	  [mmol/L]	   2.2	  (0.6)	   2.1	  (0.6)	   2.0	  (0.6)	   3.0	  (0.8)	   3.0	  (0.8)	   2.9	  (0.8)	   4.3	  (1.1)	   4.2	  (1.1)	   4.2	  (1.0)	  
rs12916	  minor	  allele	  frequency	  (C)	   43%	   40%	   40%	  
LDL	  cholesterol	  per	  rs12916-­‐T	  allele,	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Supplementary	  Table	  2	  (Continued)	  
Characteristics	  





Northern	  Finland	  Birth	  Cohort	  of	  1986	  
(NFBC-­‐1986)	  
n=4,145	  
Genotypes	   C/C	   C/T	   T/T	   C/C	   C/T	   T/T	   C/C	   C/T	   T/T	  
Number	  of	  individuals	   362	   986	   557	   856	   2221	   1326	   823	   1965	   1357	  
Male	  [%]	   44	   45	   48	   47	   48	   49	   50	   49	   51	  
Age	  [year]	   37.6	  (4.8)	   37.7	  (5.2)	   37.7	  (4.8)	   47.2	  (13.5)	   47.1	  (12.9)	   47.0	  (13.2)	   16.1	  (0.4)	   16.0	  (0.3)	   16.1	  (0.4)	  
BMI	  [kg/m2]	   25.6	  (4.7)	   26.0	  (4.7)	   26.1	  (4.8)	   26.6	  (4.4)	   26.5	  (4.5)	   26.5	  (4.5)	   21.4	  (3.5)	   21.2	  (3.5)	   21.1	  (3.2)	  
Systolic	  blood	  pressure	  [mmHg]	   121	  (15)	   121	  (14)	   120	  (14)	   135	  (19)	   135	  (20)	   135	  (20)	   116	  (13)	   115	  (13)	   116	  (13)	  
Plasma	  glucose	  [mmol/L]	   5.2	  [4.9,5.6]	   5.2	  [4.9,5.6]	   5.2	  [4.9,5.6]	   5.0	  [4.7,5.3]	   5.0	  [4.7,5.3]	   5.0	  [4.6,5.3]	   5.1	  [4.9,5.4]	   5.2	  [4.9,5.4]	   5.1	  [4.9,5.4]	  
Triglycerides	  [mmol/L]	   1.1	  [0.8,1.6]	   1.1	  [0.8,1.6]	   1.1	  [0.8,1.7]	   1.2	  [0.9,1.7]	   1.2	  [0.9,1.7]	   1.2	  [0.8,1.7]	   0.8	  [0.6,1.0]	   0.7	  [0.6,1.0]	   0.7	  [0.6,1.0]	  
Total	  cholesterol	  [mmol/L]	   5.1	  (0.9)	   5.1	  (0.9)	   4.9	  (0.8)	   5.6	  (1.1)	   5.6	  (1.0)	   5.4	  (1.0)	   4.3	  (0.8)	   4.3	  (0.8)	   4.2	  (0.8)	  
HDL	  cholesterol	  [mmol/L]	   1.3	  (0.3)	   1.3	  (0.3)	   1.3	  (0.3)	   1.4	  (0.3)	   1.4	  (0.4)	   1.4	  (0.3)	   1.4	  (0.3)	   1.4	  (0.3)	   1.4	  (0.3)	  
Friedewald	  LDL	  cholesterol	  [mmol/L]	   3.1	  (0.8)	   3.1	  (0.8)	   2.9	  (0.7)	   3.6	  (0.9)	   3.5	  (0.9)	   3.4	  (0.9)	   2.5	  (0.7)	   2.5	  (0.7)	   2.4	  (0.7)	  
rs12916	  minor	  allele	  frequency	  (C)	   47%	   45%	   44%	  
LDL	  cholesterol	  per	  rs12916-­‐T	  allele,	  	  









[-­‐0.14,	  -­‐0.052];	  	  
R	  2=0.0046	  
Values	  are	  mean	  (SD)	  and	  median	  [interquartile	  range]	  for	  normally	  distributed	  and	  skewed	  variables,	  respectively.	  P-­‐value	  of	  Hardy-­‐Weinberg	  equilibrium	  for	  
rs12196	  in	  HMGCR	  was	  P>0.01	  in	  all	  cohorts.	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Characteristics	  
Northern	  Finland	  Birth	  Cohort	  of	  1966	  
(NFBC-­‐1966)	  
n=4,920	  
Whitehall	  II	  study	  
(WHII)	  
n=3,918	  
Genotypes	   C/C	   C/T	   T/T	   C/C	   C/T	   T/T	  
Number	  of	  individuals	   936	   2432	   1552	   631	   1886	   1401	  
Male	  [%]	   51	   50	   50	   77	   73	   74	  
Age	  [year]	   31.1	  (0.4)	   31.1	  (0.3)	   31.2	  (0.4)	   55.2	  (6.0)	   55.3	  (6.0)	   55.3	  (5.8)	  
BMI	  [kg/m2]	   24.6	  (4.1)	   24.6	  (4.1)	   24.6	  (4.2)	   25.8	  (3.7)	   26.0	  (3.9)	   26.0	  (3.8)	  
Systolic	  blood	  pressure	  [mmHg]	   125	  (14)	   125	  (13)	   125	  (13)	   123	  (16)	   122	  (16)	   122	  (16)	  
Plasma	  glucose	  [mmol/L]	   5.0	  [4.8,5.3]	   5.0	  [4.7,5.3]	   5.0	  [4.7,5.3]	   5.1	  [4.7,5.4]	   5.0	  [4.7,5.4]	   5.0	  [4.7,5.3]	  
Triglycerides	  [mmol/L]	   1.0	  [0.7,1.4]	   1.0	  [0.7,1.4]	   1.0	  [0.7,1.4]	   1.1	  [0.8,1.6]	   1.1	  [0.8,1.6]	   1.1	  [0.8,1.6]	  
Total	  cholesterol	  [mmol/L]	   5.1	  (1.0)	   5.1	  (1.0)	   5.0	  (1.0)	   6.0	  (1.0)	   5.9	  (1.0)	   5.8	  (1.0)	  
HDL	  cholesterol	  [mmol/L]	   1.5	  (0.4)	   1.5	  (0.4)	   1.6	  (0.4)	   1.5	  (0.4)	   1.5	  (0.4)	   1.5	  (0.4)	  
Friedewald	  LDL	  cholesterol	  [mmol/L]	   3.0	  (0.9)	   3.0	  (0.9)	   2.9	  (0.9)	   4.0	  (0.9)	   3.9	  (0.9)	   3.8	  (0.9)	  
rs12916	  minor	  allele	  frequency	  (C)	   45%	   40%	  
LDL	  cholesterol	  per	  rs12916-­‐T	  allele,	  	  








Values	  are	  mean	  (SD)	  and	  median	  [interquartile	  range]	  for	  normally	  distributed	  and	  skewed	  variables,	  respectively.	  P-­‐value	  of	  Hardy-­‐Weinberg	  equilibrium	  for	  
rs12196	  in	  HMGCR	  was	  P>0.01	  in	  all	  cohorts.	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Supplementary	  Figure	  1.	  Representative	  NMR	  spectra	  before	  and	  after	  statin	  use.	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Example	  of	  the	  three	  NMR	  spectral	  windows	  (LIPO,	  LMWM	  and	  LIPID)	  measured	  by	  the	  
high-­‐throughput	  serum	  metabolomics	  platform.19	  The	  spectral	  data	  are	  shown	  for	  a	  single	  
individual	  before	  and	  after	  starting	  statin	  therapy.	  An	  individual	  with	  a	  large	  absolute	  
change	  in	  LDL-­‐C	  (-­‐2.6	  mmol/L)	  was	  chosen	  to	  visually	  emphasize	  effects	  of	  statin	  use	  on	  the	  
spectral	  characteristics.	  The	  figure	  is	  meant	  only	  to	  exemplify	  the	  overall	  characteristics	  of	  
the	  NMR	  spectral	  data	  and	  illustrate	  the	  approximate	  molecular	  content	  as	  well	  as	  signal	  
assignments.	  All	  statistical	  data	  analyses	  were	  conducted	  based	  on	  the	  lipoprotein,	  lipid	  and	  
metabolite	  measures	  quantified	  in	  absolute	  concentration	  units.	  No	  direct	  analysis	  of	  statin	  
effects	  on	  the	  spectral	  data	  were	  performed	  —	  the	  metabolic	  biomarker	  data	  were	  analyzed	  
in	  the	  present	  study	  similarly	  as	  for	  any	  other	  quantitative	  clinical	  chemistry	  measure.	  
	  
The	  LIPO	  window	  is	  acquired	  from	  a	  native	  serum	  sample.	  It	  is	  dominated	  by	  broad	  signals	  
arising	  from	  macromolecules,	  mainly	  lipoprotein	  lipids	  and	  albumin.	  Despite	  the	  broad	  
overall	  characteristics	  and	  substantial	  overlap	  of	  the	  resonances,	  appropriate	  data	  analyses	  
provide	  abundant	  information	  on	  lipoprotein	  particles	  as	  indicated	  by	  the	  inset	  illustrating	  
the	  lipoprotein	  subclasses.	  The	  particle	  sizes	  range	  from	  diameters	  of	  ~8	  nm	  for	  the	  smallest	  
HDL	  particles	  to	  >80	  nm	  for	  the	  largest	  VLDL	  particles.	  The	  LMWM	  window	  is	  also	  acquired	  
from	  the	  native	  serum	  sample	  using	  a	  special	  NMR	  pulse	  sequence,	  which	  suppresses	  most	  
of	  the	  broad	  macromolecule	  and	  lipoprotein	  lipid	  signals.	  This	  enhances	  the	  detection	  and	  
quantification	  of	  rapidly	  tumbling	  smaller	  solutes.	  The	  LMWM	  spectrum	  shows	  signals	  from	  
various	  low-­‐molecular-­‐weight	  molecules	  as	  well	  as	  some	  lipid	  resonances	  representing	  the	  
most	  mobile	  lipid	  molecules	  in	  the	  lipoprotein	  particles.	  The	  LIPID	  window	  is	  run	  separately	  
from	  serum	  lipid	  extracts;	  the	  extraction	  procedure	  breaks	  down	  the	  lipoprotein	  particles	  
yielding	  information	  on	  the	  individual	  lipid	  species	  inside	  the	  particles.	  
	  
The	  spectra	  are	  shown	  in	  red	  for	  the	  measurement	  before	  statin	  use	  and	  in	  blue	  for	  the	  
measurement	  after	  initiation	  of	  statin	  therapy.	  The	  large	  decrease	  in	  LDL-­‐C	  (-­‐2.6	  mmol/L)	  is	  
evident	  from	  all	  the	  key	  lipid	  resonances	  between	  0.5	  and	  3.2	  ppm	  in	  the	  LIPO	  spectrum;	  
the	  –CH3	  resonance	  is	  shown	  in	  an	  inset	  in	  the	  top	  right-­‐hand	  corner	  of	  the	  figure.	  The	  lipids	  
in	  the	  IDL	  and	  LDL	  subclasses	  give	  rise	  to	  their	  most	  pronounced	  resonances	  in	  the	  middle	  of	  
the	  –CH3	  peak	  where	  the	  largest	  difference	  between	  the	  spectra	  are	  apparent.	  For	  this	  
person,	  also	  serum	  triglycerides	  decreased	  (-­‐0.7	  mmol/L)	  after	  starting	  statin	  treatment;	  this	  
is	  also	  evident	  from	  the	  lipid	  resonances,	  e.g.,	  on	  the	  left-­‐hand	  side	  of	  the	  –CH3	  peak,	  where	  
the	  triglyceride-­‐rich	  VLDL	  subclasses	  give	  rise	  to	  their	  main	  spectral	  contribution.	  In	  
accordance	  with	  the	  overall	  results	  shown	  in	  Figure	  3,	  there	  are	  very	  little	  differences	  
between	  the	  spectra	  in	  the	  LMWM	  window.	  The	  only	  exception	  hereof	  is	  a	  reflection	  of	  the	  
decrease	  in	  the	  mobile	  lipids,	  mainly	  VLDL-­‐related	  triglycerides.	  In	  contrast	  hereto,	  marked	  
differences	  are	  observed	  throughout	  the	  LIPID	  window.	  These	  reflect	  the	  overall	  results	  
shown	  in	  Figure	  2,	  namely	  that	  the	  absolute	  concentrations	  of	  all	  fatty	  acid	  measures	  
decrease	  along	  with	  starting	  statin	  therapy.	  This	  is	  a	  direct	  consequence	  of	  large	  decreases	  
in	  lipoprotein	  cholesterol	  and	  triglyceride	  concentrations.	  
	  
Abbreviations:	  EC,	  esterified	  cholesterol;	  FA,	  fatty	  acid;	  FC,	  free	  cholesterol;	  HDL,	  high-­‐
density	  lipoprotein;	  IDL,	  intermediate-­‐density	  lipoprotein;	  LDL,	  low-­‐density	  lipoprotein;	  
MUFA,	  monounsaturated	  fatty	  acids;	  PC,	  phosphatidylcholine;	  PGLY,	  phosphoglycerides;	  
PUFA,	  polyunsaturated	  fatty	  acids;	  sat,	  saturated;	  SM,	  sphingomyelin;	  TC,	  total	  serum	  
cholesterol;	  TG,	  total	  serum	  triglycerides;	  TGLY,	  TG	  backbone;	  VLDL,	  very-­‐low-­‐density	  
lipoprotein.	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Supplementary	  Figure	  2.	  Lipid	  and	  metabolite	  changes	  associated	  with	  starting	  statin	  
therapy	  relative	  to	  baseline	  concentrations.	  
	  
Lipoprotein,	  fatty	  acid	  and	  metabolite	  concentration	  changes	  associated	  with	  starting	  statin	  
therapy	  in	  percentage	  change	  relative	  to	  baseline	  concentrations.	  The	  relative	  
concentration	  changes	  were	  assessed	  in	  each	  of	  the	  four	  longitudinal	  cohorts	  with	  
adjustment	  for	  age	  and	  sex,	  and	  subsequently	  meta-­‐analyzed.	  Error	  bars	  denote	  95%	  
confidence	  intervals.	  Circles	  without	  visible	  error	  bars	  indicate	  that	  the	  confidence	  intervals	  
are	  within	  the	  symbols.	  Wide	  confidence	  intervals	  arise	  for	  some	  metabolic	  measures	  with	  
very	  low	  concentrations	  and	  highly	  skewed	  distributions.
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Supplementary	  Figure	  3A-­‐F.	  Lipid	  and	  metabolite	  changes	  associated	  with	  starting	  statin	  
therapy	  and	  rs12196	  in	  HMGCR	  separately	  for	  the	  individual	  cohorts.	  
	  
Supplementary	  Figure	  3A.	  Left:	  Lipoprotein	  changes	  associated	  with	  starting	  statin	  therapy	  
in	  the	  four	  cohorts	  with	  profiling	  at	  two	  time-­‐points.	  Associations	  were	  adjusted	  for	  age	  and	  
sex.	  Results	  are	  shown	  in	  SD-­‐scaled	  concentration	  units.	  
Right:	  Lipoprotein	  associations	  with	  rs12196	  in	  HMGCR	  in	  the	  eight	  individual	  cohorts.	  
Associations	  were	  adjusted	  for	  age,	  sex,	  and	  population	  stratification.	  Results	  are	  shown	  in	  
SD-­‐scaled	  concentration	  units.	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Supplementary	  Figure	  3B.	  Left:	  Lipoprotein	  lipid	  changes	  associated	  with	  starting	  statin	  
therapy	  in	  the	  four	  cohorts	  with	  profiling	  at	  two	  time-­‐points.	  Associations	  were	  adjusted	  for	  
age	  and	  sex.	  Results	  are	  shown	  in	  SD-­‐scaled	  concentration	  units.	  
Right:	  Lipoprotein	  lipid	  associations	  with	  rs12196	  in	  HMGCR	  in	  the	  eight	  individual	  cohorts.	  
Associations	  were	  adjusted	  for	  age,	  sex,	  and	  population	  stratification.	  Results	  are	  shown	  in	  
SD-­‐scaled	  concentration	  units.
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Supplementary	  Figure	  3C.	  Left:	  Lipoprotein	  lipid	  changes	  associated	  with	  starting	  statin	  
therapy	  in	  the	  four	  cohorts	  with	  profiling	  at	  two	  time-­‐points.	  Associations	  were	  adjusted	  for	  
age	  and	  sex.	  Results	  are	  shown	  in	  SD-­‐scaled	  concentration	  units.	  
Right:	  Lipoprotein	  lipid	  associations	  with	  rs12196	  in	  HMGCR	  in	  the	  eight	  individual	  cohorts.	  
Associations	  were	  adjusted	  for	  age,	  sex,	  and	  population	  stratification.	  Results	  are	  shown	  in	  
SD-­‐scaled	  concentration	  units.
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Supplementary	  Figure	  3D.	  Left:	  Lipoprotein	  and	  fatty	  acid	  changes	  associated	  with	  starting	  
statin	  therapy	  in	  the	  four	  cohorts	  with	  profiling	  at	  two	  time-­‐points.	  Associations	  were	  
adjusted	  for	  age	  and	  sex.	  Results	  are	  shown	  in	  SD-­‐scaled	  concentration	  units.	  
Right:	  Lipoprotein	  and	  fatty	  acid	  associations	  with	  rs12196	  in	  HMGCR	  in	  the	  eight	  individual	  
cohorts.	  Associations	  were	  adjusted	  for	  age,	  sex,	  and	  population	  stratification.	  Results	  are	  
shown	  in	  SD-­‐scaled	  concentration	  units.
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Supplementary	  Figure	  3E.	  Left:	  Fatty	  acid	  and	  metabolite	  changes	  associated	  with	  starting	  
statin	  therapy	  in	  the	  four	  cohorts	  with	  profiling	  at	  two	  time-­‐points.	  Associations	  were	  
adjusted	  for	  age	  and	  sex.	  Results	  are	  shown	  in	  SD-­‐scaled	  concentration	  units.	  
Right:	  Fatty	  acid	  and	  metabolite	  associations	  with	  rs12196	  in	  HMGCR	  in	  the	  eight	  individual	  
cohorts.	  Associations	  were	  adjusted	  for	  age,	  sex,	  and	  population	  stratification.	  Results	  are	  
shown	  in	  SD-­‐scaled	  concentration	  units.
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Supplementary	  Figure	  3F.	  Left:	  Metabolite	  changes	  associated	  with	  starting	  statin	  therapy	  
in	  the	  four	  cohorts	  with	  profiling	  at	  two	  time-­‐points.	  Associations	  were	  adjusted	  for	  age	  and	  
sex.	  Results	  are	  shown	  in	  SD-­‐scaled	  concentration	  units.	  
Right:	  Metabolite	  associations	  with	  rs12196	  in	  HMGCR	  in	  the	  eight	  individual	  cohorts.	  
Associations	  were	  adjusted	  for	  age,	  sex,	  and	  population	  stratification.	  Results	  are	  shown	  in	  
SD-­‐scaled	  concentration	  units.
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Supplementary	  Figure	  4.	  Lipid	  and	  metabolite	  changes	  associated	  with	  starting	  statin	  
therapy	  when	  adjusted	  for	  additional	  cardiovascular	  risk	  factors.	  
	  
Supplementary	  Figure	  4A:	  Lipid	  changes	  associated	  with	  starting	  statin	  therapy	  according	  to	  
three	  models:	  1)	  adjusted	  for	  age	  and	  sex	  (magenta);	  2)	  adjusted	  for	  age,	  sex	  and	  change	  in	  
BMI	  during	  follow-­‐up	  (purple);	  and	  3)	  adjusted	  for	  age,	  sex	  and	  baseline	  BMI,	  systolic	  blood	  
pressure,	  smoking	  status,	  diabetes	  status	  and	  LDL-­‐C	  (green).	  Results	  were	  meta-­‐analyzed	  for	  
the	  four	  longitudinal	  cohorts.	  Association	  magnitudes	  are	  shown	  in	  SD-­‐scaled	  concentration	  
units.	  Error	  bars	  denote	  95%	  confidence	  intervals.
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Supplementary	  Figure	  4B:	  Lipid	  and	  metabolite	  changes	  associated	  with	  starting	  statin	  
therapy	  according	  to	  three	  models:	  1)	  adjusted	  for	  age	  and	  sex	  (magenta);	  2)	  adjusted	  for	  
age,	  sex	  and	  change	  in	  BMI	  during	  follow-­‐up	  (purple);	  and	  3)	  adjusted	  for	  age,	  sex	  and	  
baseline	  BMI,	  systolic	  blood	  pressure,	  smoking	  status,	  diabetes	  status	  and	  LDL-­‐C	  (green).	  
Results	  were	  meta-­‐analyzed	  for	  the	  four	  longitudinal	  cohorts.	  Association	  magnitudes	  are	  
shown	  in	  SD-­‐scaled	  concentration	  units.	  Error	  bars	  denote	  95%	  confidence	  intervals.
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Supplementary	  Figure	  5.	  Comparison	  of	  lipid	  and	  metabolite	  associations	  for	  two	  common	  
genetic	  variants	  in	  the	  HMGCR	  gene.	  
	  
Lipoprotein,	  fatty	  acid	  and	  metabolite	  associations	  with	  two	  SNPs,	  rs12196	  and	  
rs17238484,	  in	  the	  HMGCR	  gene	  (linkage-­‐disequilibrium	  R2=0.35).	  The	  results	  are	  for	  meta-­‐
analysis	  in	  the	  eight	  population-­‐based	  cohorts	  (n=27,914).	  The	  metabolic	  associations	  were	  
assessed	  by	  linear	  regression	  models	  adjusted	  for	  age,	  sex	  and	  population	  stratification.	  
Error	  bars	  denote	  95%	  confidence	  intervals.	  rs3761742	  was	  used	  as	  proxy	  for	  rs17238484	  
for	  NFBC-­‐1986	  and	  BWHHS	  (linkage	  disequilibrium	  R2=1).	  rs698912	  was	  used	  as	  proxy	  for	  
rs17238484	  in	  the	  ALSPAC	  children	  and	  mothers	  cohorts	  (linkage	  disequilibrium	  R2=1).	  





















































































































Omega−3 fatty acids (%)
Linoleic acid (%)
Omega−6 fatty acids (%)
PUFA (%)
MUFA (%)



























































Lipoprot i article size
Apolipop ins
Fatty acid






Branched−chain a ino acids
Aro atic a ino acids
SD difference (95%CI) per HMGCR  allele
rs12916: P < 0.0006 P ≥ 0.0006
● ●rs17238484: P < 0.0006 P ≥ 0.0006
